LADONNA HART: Open Payments
NPI 1891808721 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$570 in 22 payments from 8 companies in 2025. Trend: 2023 $799 · 2024 $733 · 2025 $570
Food & beverage: $570
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $314 |
| Novo Nordisk Inc | 3 | $141 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Janssen Pharmaceuticals, Inc | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| PFIZER INC. | 1 | $15 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $14 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $14 |
Products named: VRAYLAR, UBRELVY, Ozempic, QULIPTA, REXULTI, Wegovy, SPRAVATO, Rybelsus.
Industry payments across NE — which companies pay providers there.
